A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.

NCT05387980 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1128

Last updated 2026-03-19

No results posted yet for this study

Summary

The purpose of this study is to learn about the safety and effectiveness (how well the study treatment works) of the study medicine (CIBINQO) for the potential treatment of atopic dermatitis in people under Japanese medical practice.

Conditions

Interventions

DRUG

CIBINQO

Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-19
Primary Completion
2028-11-01
Completion
2028-11-01

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05387980 on ClinicalTrials.gov